Literature DB >> 21601725

Toward a more comprehensive assessment of depression remission: the Remission Evaluation and Mood Inventory Tool (REMIT).

Donald E Nease1, James E Aikens, Michael S Klinkman, Kurt Kroenke, Ananda Sen.   

Abstract

OBJECTIVE: Depression remission continues to be defined in terms of resolution of the Diagnostic and Statistical Manual of Mental Disorders criteria symptoms. However, it may be useful to assess additional symptoms as part of a more complete evaluation of remission. We sought to develop an adjunct self-report measure that can be used with commonly used depression measures when assessing remission.
METHODS: Secondary data analysis and expert input were used to develop candidate items that were evaluated cross-sectionally in 1003 primary care clinician-identified depressed patients from two practice-based research networks. Multivariable regression analysis, with self-assessed recovery as the dependent variable, identified five symptoms that contributed significantly beyond the Patient Health Questionnaire (PHQ)-8. Further analysis was performed in selected subsamples.
RESULTS: Emotional control, contentedness, future seeming dark, ability to bounce back and happiness yielded an 11% increase in R(2) beyond 60% yielded by the PHQ-8. The summed Remission Evaluation and Mood Inventory Tool (REMIT) 5 items have a mean=9.6 (S.D.=4.5), range 0-20 and reliability of 0.86. Subsample analysis showed incremental R(2) ranging from 9% in men to 15% in African-Americans.
CONCLUSION: Depression remission is a multidimensional concept that includes important nondepressive symptom dimensions. These important dimensions can be measured using a self-report instrument feasible for routine primary care. Pending longitudinal validation, REMIT5 is a promising tool for depression management.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21601725     DOI: 10.1016/j.genhosppsych.2011.03.002

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  5 in total

1.  The Appalachia Mind Health Initiative (AMHI): a pragmatic randomized clinical trial of adjunctive internet-based cognitive behavior therapy for treating major depressive disorder among primary care patients.

Authors:  Robert M Bossarte; Ronald C Kessler; Andrew A Nierenberg; Ambarish Chattopadhyay; Pim Cuijpers; Angel Enrique; Phyllis M Foxworth; Sarah M Gildea; Bea Herbeck Belnap; Marc W Haut; Kari B Law; William D Lewis; Howard Liu; Alexander R Luedtke; Wilfred R Pigeon; Larry A Rhodes; Derek Richards; Bruce L Rollman; Nancy A Sampson; Cara M Stokes; John Torous; Tyler D Webb; Jose R Zubizarreta
Journal:  Trials       Date:  2022-06-20       Impact factor: 2.728

2.  Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study.

Authors:  Alonso Montoya; Jeremie Lebrec; Karen Mary Keane; Irene Fregenal; Antonio Ciudad; Ángel Moríñigo; Luis Agüera-Ortiz; Irene Romera; Inmaculada Gilaberte; Mark Zimmerman
Journal:  BMC Psychiatry       Date:  2016-10-19       Impact factor: 3.630

3.  Comparing five depression measures in depressed Chinese patients using item response theory: an examination of item properties, measurement precision and score comparability.

Authors:  Yue Zhao; Wai Chan; Barbara Chuen Yee Lo
Journal:  Health Qual Life Outcomes       Date:  2017-04-04       Impact factor: 3.186

4.  Knowledge of HIV Status Is Associated With a Decrease in the Severity of Depressive Symptoms Among Female Sex Workers in Uganda and Zambia.

Authors:  Katrina F Ortblad; Daniel Kibuuka Musoke; Michael M Chanda; Thomson Ngabirano; Jennifer Velloza; Jessica E Haberer; Margaret McConnell; Catherine E Oldenburg; Till Bärnighausen
Journal:  J Acquir Immune Defic Syndr       Date:  2020-01-01       Impact factor: 3.771

5.  Excess burden of depression among HIV-infected persons receiving medical care in the united states: data from the medical monitoring project and the behavioral risk factor surveillance system.

Authors:  Ann N Do; Eli S Rosenberg; Patrick S Sullivan; Linda Beer; Tara W Strine; Jeffrey D Schulden; Jennifer L Fagan; Mark S Freedman; Jacek Skarbinski
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.